Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
34 hedge funds and large institutions have $45.5M invested in Cymabay Therapeutics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
278% more capital invested
Capital invested by funds: $12M → $45.5M (+$33.5M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more funds holding
Funds holding: 27 → 34 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.27M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.17M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$2.23M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$1.43M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$1.63M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$353K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$143K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.49K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| $71K | +$47.1K | +16,404 | New |
|
|
SPC
27
Sigma Planning Corp
Ann Arbor,
Michigan
| $61K | +$40.4K | +14,085 | New |
|
|
LCM
28
LVM Capital Management
Portage,
Michigan
| $43K | +$28.7K | +10,000 | New |
|
|
AIM
29
Acrospire Investment Management
Chicago,
Illinois
| $42K | -$2.38K | -831 | -8% |
|
|
LTFS
30
Ladenburg Thalmann Financial Services
Miami,
Florida
| $28K | +$14.3K | +5,000 | +348% |
|
|
FPF
31
FNY Partners Fund
New York
| $23K | +$15.8K | +5,500 | New |
|
|
32
UBS Group
Zurich,
Switzerland
| $16K | -$9.49K | -3,310 | -47% |
|
33
Federated Hermes
Pittsburgh,
Pennsylvania
| $9K | +$6.08K | +2,121 | New |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
KCM
35
Kingdon Capital Management
New York
| – | -$1.63M | -941,348 | Closed |
|
|
36
AllianceBernstein
Nashville,
Tennessee
| – | -$353K | -204,256 | Closed |
|
|
37
Creative Planning
Overland Park,
Kansas
| – | -$7K | -4,000 | Closed |
|
38
Parallax Volatility Advisers
San Francisco,
California
| – | -$3K | -1,764 | Closed |
|
CBAY Hedge Fund Activity: Q1 2017 in Review
34 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2017, worth a combined $45.5M — up 278% from $12M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CBAY positions and 5 closed out — a net gain of 10 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $3.27M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $1.63M sold.
- 34 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2017, up from 27 in Q4 2016.
- Funds reported $45.5M of Cymabay Therapeutics stock for Q1 2017, up 278% quarter-over-quarter.
- 15 funds opened new Cymabay Therapeutics positions in Q1 2017 and 5 closed out, a net change of +10 holders.
- The largest Cymabay Therapeutics buyer in Q1 2017 was Adage Capital Partners, an estimated $3.27M added.
- The largest Cymabay Therapeutics seller in Q1 2017 was Kingdon Capital Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2017.